Search Results
Search for other papers by Judith A Gilbert in
Google Scholar
PubMed
Search for other papers by Laura J Adhikari in
Google Scholar
PubMed
Search for other papers by Ricardo V Lloyd in
Google Scholar
PubMed
Search for other papers by Joseph Rubin in
Google Scholar
PubMed
Search for other papers by Paul Haluska in
Google Scholar
PubMed
Search for other papers by Joan M Carboni in
Google Scholar
PubMed
Search for other papers by Marco M Gottardis in
Google Scholar
PubMed
Search for other papers by Matthew M Ames in
Google Scholar
PubMed
immunohistochemical staining (intensity score of 3) for the ten molecular markers studied. Hsp90, TGFBR1, IGF1R, and SSTR5 (the strongest staining biomarkers for the largest number of NETs) were expressed in all tumors from 20 cases in which primary and metastatic
Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland
Search for other papers by Dermot O'Toole in
Google Scholar
PubMed
Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Vinciane Rebours in
Google Scholar
PubMed
Search for other papers by Magali Zappa in
Google Scholar
PubMed
Search for other papers by Olivia Hentic in
Google Scholar
PubMed
Search for other papers by Pascal Hammel in
Google Scholar
PubMed
Search for other papers by Philippe Levy in
Google Scholar
PubMed
Department of Clinical Medicine and Gastroenterology, Service de Gastroentérologie, Service d'Anatomie Pathologique, INSERM U773, Service de Radiologie, Service d'Oncologie Bichat-Beaujon, St James's Hospital and Trinity College Dublin, James's Street, Dublin 8, Ireland
Search for other papers by Pierre Bedossa in
Google Scholar
PubMed
Search for other papers by Eric Raymond in
Google Scholar
PubMed
Search for other papers by Philippe Ruszniewski in
Google Scholar
PubMed
aggressive GEP-NETs but their influence on therapy is unknown. Several putative molecular markers predicting either sensitivity or resistance to oncological therapeutics have been proposed. The multidrug resistance protein and other ABC transporters have well
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Andreas Venizelos in
Google Scholar
PubMed
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
Search for other papers by Hege Elvebakken in
Google Scholar
PubMed
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Oleksii Nikolaienko in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Wei Deng in
Google Scholar
PubMed
Search for other papers by Inger Marie B Lothe in
Google Scholar
PubMed
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Geir Olav Hjortland in
Google Scholar
PubMed
Department of Medical Radiation Physics, Lund University, Lund, Sweden
Search for other papers by Anna Sundlöv in
Google Scholar
PubMed
Search for other papers by Johanna Svensson in
Google Scholar
PubMed
Search for other papers by Harrish Garresori in
Google Scholar
PubMed
Search for other papers by Christian Kersten in
Google Scholar
PubMed
Department of Oncology, St.Olavs Hospital, Trondheim, Norway
Search for other papers by Eva Hofsli in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Search for other papers by Sönke Detlefsen in
Google Scholar
PubMed
Search for other papers by Merete Krogh in
Google Scholar
PubMed
Department of Clinical Science, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Stian Knappskog in
Google Scholar
PubMed
have associated microsatellite instability (MSI) with improved prognosis ( La Rosa et al. 2012 , Sahnane et al. 2015 ). However, molecular markers for classification, treatment selection and prognosis for HG GEP-NEN are generally lacking. Some
Search for other papers by Susan J Hsiao in
Google Scholar
PubMed
Search for other papers by Yuri E Nikiforov in
Google Scholar
PubMed
need for molecular markers The diagnosis of thyroid cancer is typically obtained through ultrasound examination and fine-needle aspiration (FNA) biopsy of suspicious nodules. Cytological examination of cells collected by FNA biopsy is the most reliable
Search for other papers by P J Barrett-Lee in
Google Scholar
PubMed
other candidate markers for a way forward. Molecular markers for chemotherapy response At the present time, no single predictive biological marker has become established in routine practice in breast cancer to assess clinical
Search for other papers by Ruth Foley in
Google Scholar
PubMed
Search for other papers by Donal Hollywood in
Google Scholar
PubMed
Search for other papers by Mark Lawler in
Google Scholar
PubMed
mechanisms, including cross-activation by agents such as IGF-I ( Culig et al. 1994 ). Potential new molecular markers such as hepsin ( Rhodes et al. 2002 ) have been identified. These and other identified and novel genes implicated in the disease
Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France
Search for other papers by Bruno Ragazzon in
Google Scholar
PubMed
Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France
Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France
Search for other papers by Guillaume Assié in
Google Scholar
PubMed
Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France
Institut Cochin, Inserm, Department of Endocrinology, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France
Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed
et al . 1993 , Rainier et al . 1993 , Gicquel et al . 1997 ). Interestingly, it has been previously demonstrated that IGF2 expression could be used as a molecular marker for the diagnosis of ACC ( Gicquel et al . 2001 ). The IGF signaling pathway
Search for other papers by C J Fabian in
Google Scholar
PubMed
Search for other papers by B F Kimler in
Google Scholar
PubMed
Search for other papers by M S Mayo in
Google Scholar
PubMed
Search for other papers by S A Khan in
Google Scholar
PubMed
and/or RPFNA, there is a great deal of interest in supplementing morphologic interpretations with molecular markers ( Fabian et al. 2002 , Ljung et al. 2004 , Gornstein et al. 2004 , Sneige 2004 ). Simple assessment of ploidy has been
Search for other papers by Maria P Yavropoulou in
Google Scholar
PubMed
Search for other papers by Marina Tsoli in
Google Scholar
PubMed
Search for other papers by Konstantinos Barkas in
Google Scholar
PubMed
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
Search for other papers by Ashley Grossman in
Google Scholar
PubMed
play increasing roles. Highly aggressive tumours will need particular care, including the use of TMZ and newer agents. What is clear is that we need molecular markers able to predict future behaviour, and these are still unavailable. Perhaps the next
Search for other papers by H Yamashita in
Google Scholar
PubMed
Search for other papers by M Nishio in
Google Scholar
PubMed
Search for other papers by Y Ando in
Google Scholar
PubMed
Search for other papers by Z Zhang in
Google Scholar
PubMed
Search for other papers by M Hamaguchi in
Google Scholar
PubMed
Search for other papers by K Mita in
Google Scholar
PubMed
Search for other papers by S Kobayashi in
Google Scholar
PubMed
Search for other papers by Y Fujii in
Google Scholar
PubMed
Search for other papers by H Iwase in
Google Scholar
PubMed
strong prognostic molecular marker in ER-positive breast cancer. Positive Stat5 expression predicts response to endocrine therapy and increases post-relapse survival in metastatic breast cancer patients who received first-line treatment with endocrine